Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for ...

Last week, BioVie announced a significant milestone: a Notice of Allowance from the Japan Patent Office for its application regarding a novel liquid formulation of terlipressin. This formulation, ...

Metabolic dysfunction-associated steatotic liver disease (MASLD)—previously known as "non-alcoholic fatty liver ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

Madrigal Pharmaceuticals (MDGL) announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated ...

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

Genflow Biosciences PLC on Tuesday said it has secured EUR4 million in funding from the Wallonia region in Belgium, to support its gene therapy development work. The London-based biotechnology company ...

Blocking the enzyme ACMSD can significantly reduce damage caused by metabolic liver disease according to a new study.

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for cardiovascular disease – the leading cause of death worldwide.   University of Leeds ...

A New 3D Bioprinted Model Offers a Novel Tool to Study Common Liver Disease, and Perhaps Find an Effective Treatment Jan. 23, 2024 — Metabolic dysfunction--associated steatohepatitis or MASH ...